Home > Insider Trading > Filing (0000899243-17-026034)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492422	Apellis Pharmaceuticals Inc.	APLS	Pharmaceutical Preparations (2834)	271537290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1634632	L.p. Ii Fund Strategic Global Venbio	1700 Owens Street, Suite 595 San Francisco CA 94158		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-13	3,451,790	$0.00	3,451,790	No	4	C	Direct
Common Stock	Acquisiton	2017-11-13	127,515	$14.00	3,579,305	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Preferred Stock	Disposition	2017-11-13	6,714,413	$0.00	3,147,872	$0.00
Common Stock	Series E Preferred Stock	Disposition	2017-11-13	648,256	$0.00	303,917	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

The Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Robert Adelman and Corey Goodman, the managing partners of venBio Global Strategic Fund II LP ("venBio"), share voting and dispositive control over the shares held by venBio.